Compare Sana Biotechnology Inc (SANA) vs iShares TIPS Bond ETF (TIP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sana Biotechnology Inc vs iShares TIPS Bond ETF — how do they compare? Sana Biotechnology Inc trades at $2.79 (market cap $812.76M), while iShares TIPS Bond ETF trades at $104.65 (market cap $14.16B). The key difference: iShares TIPS Bond ETF is far larger — about 17.4× Sana Biotechnology Inc's market cap, and Sana Biotechnology Inc is more actively traded (4,314,200 versus 1,695,817). Which is the better fit depends on your goals — on Pluang, investors hold Sana Biotechnology Inc for 23 Days and iShares TIPS Bond ETF for 61 Days on average.
| SANA | TIP | |
|---|---|---|
Market Cap | $812.76M | $14.16B |
Volume | 4,314,200 | 1,695,817 |
Sector | Health | Fixed Income |
52-Week High | $5.92 | $112.20 |
52-Week Low | $2.68 | $103.98 |
Typical Hold Time | 23 Days | 61 Days |
Enterprise Value | $726.01M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SANA Biotechnology trades at $2.72, down 1.09% today, showing bearish technical signals with negative moving averages but oversold RSI readings. The company reported no revenue in 2025 with substantial losses (-$244.17M net income) and negative cash flow (-$55.33M), though analyst sentiment remains positive with 82% buy ratings. Recent investor conference presentations highlight ongoing clinical development activities.
While analyst consensus is bullish with a $9.50 price target (Defense World, July 30, 2026), SANA faces significant fundamental challenges including negative profitability metrics and cash burn. Investment appeal hinges on clinical pipeline success, with risks including execution challenges and the pre-revenue biotech business model requiring continued financing.
TIP trades at $104.24, showing minimal daily movement with a 0.06% gain. Technical indicators signal a bearish trend, while oscillators remain neutral. The ETF's financial ratios are not available in the provided data, limiting fundamental assessment. A dividend of $0.78 is scheduled for August 2026, indicating income potential amid current market volatility driven by rising bond yields and geopolitical tensions.
Outlook is cautious due to bearish technicals and macroeconomic pressures from high Treasury yields. The dividend offers a yield cushion, but investors face risks from bond market instability and inflationary concerns. Monitoring Federal Reserve policy and inflation data is critical for near-term direction.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →About iShares TIPS Bond ETF
TIP is the flagship ETF for U.S. Treasury Inflation-Protected Securities (TIPS). It tracks an index of government bonds whose principal value adjusts based on the Consumer Price Index (CPI), providing a direct hedge against rising inflation.
Read more on TIP →
